uniQure director sells shares after option exercise

Q: Was Jack Kaye’s uniQure (QURE) share sale under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed under a sales plan adopted on June 16, 2025 and intended to comply with Rule 10b5-1, indicating the June 17, 2026 trades were pre-arranged rather than discretionary.

uniQure N.V. director Jack Kaye exercised stock options and sold the resulting shares in a coordinated transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

uniQure N.V. director Jack Kaye exercised stock options and sold the resulting shares in a coordinated transaction. On June 17, 2026, he exercised options for 5,295 Ordinary Shares at $31.71 per share and then sold the same 5,295 shares in the open market at a weighted average price of $42.57, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025.

Following these transactions, Kaye directly holds 25,996 Ordinary Shares of uniQure. The exercised stock option, which vested in full on January 25, 2020 and had an expiration date of January 25, 2029, now shows zero remaining derivative balance.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,295 shares ($58K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Kaye Jack

Role Director

Sold 5,295 shs ($225K)

Approx. gross sale proceeds $225K

Approx. exercise cost $168K

Approx. pre-tax spread $58K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	5,295	$0.00	$0.00
Exercise	Ordinary Shares	5,295	$31.71	$168K
Sale	Ordinary Shares	5,295	$42.57	$225K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Ordinary Shares — 25,996 shares (Direct)

Footnotes (3)

F1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.50 to $42.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F3. The Stock Option vested in full on January 25, 2020.

Key Figures

Shares sold: 5,295 shares Sale price (weighted average): $42.57/share Options exercised: 5,295 shares +4 more

7 metrics

Shares sold 5,295 shares Ordinary Shares sold on June 17, 2026

Sale price (weighted average) $42.57/share Open-market sale price range $42.50–$42.83

Options exercised 5,295 shares Stock Option (Right to Buy) exercised June 17, 2026

Option exercise price $31.71/share Conversion or exercise price for Stock Option

Shares owned after 25,996 shares Direct Ordinary Share holdings following transactions

Rule 10b5-1 plan adoption date June 16, 2025 Sales plan adoption date cited in footnote

Option expiration date January 25, 2029 Original expiration for exercised Stock Option

Key Terms

Rule 10b5-1, weighted average price, Stock Option (Right to Buy), Ordinary Shares

4 terms

Rule 10b5-1 regulatory

"intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with underlying security title Ordinary Shares"

Ordinary Shares financial

"security_title: Ordinary Shares and underlying_security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did uniQure (QURE) director Jack Kaye report in this Form 4?

Director Jack Kaye reported exercising stock options for 5,295 uniQure Ordinary Shares at $31.71, then selling the same 5,295 shares at a weighted average price of $42.57 on June 17, 2026 under a Rule 10b5-1 plan.

How many uniQure (QURE) shares did Jack Kaye sell and at what price?

Jack Kaye sold 5,295 uniQure Ordinary Shares at a weighted average price of $42.57. The sales occurred in multiple trades between $42.50 and $42.83, as disclosed, all executed on June 17, 2026 in open-market transactions.

What stock options did Jack Kaye exercise in uniQure (QURE)?

He exercised a Stock Option (Right to Buy) covering 5,295 Ordinary Shares at an exercise price of $31.71 per share. The option had vested fully on January 25, 2020, with an original expiration date of January 25, 2029 before this exercise.

How many uniQure (QURE) shares does Jack Kaye own after these transactions?

After exercising options and selling 5,295 shares, Jack Kaye directly owns 25,996 uniQure Ordinary Shares. This figure reflects his direct holdings immediately following the June 17, 2026 transactions reported in this Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 07:54 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Jack

(Last)

(First)

(Middle)

C/O UNIQURE N.V.

PAASHEUVELWEG 25A

(Street)

AMSTERDAM

1105BP

(City)

(State)

(Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/17/2026		M⁽¹⁾		5,295	A	$31.71	31,291	D
Ordinary Shares	06/17/2026		S⁽¹⁾		5,295	D	$42.57⁽²⁾	25,996	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$31.71	06/17/2026		M⁽¹⁾			5,295	⁽³⁾	01/25/2029	Ordinary Shares	5,295	$0	0	D

Explanation of Responses:

1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.50 to $42.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.

3. The Stock Option vested in full on January 25, 2020.

	/s/ Christian Klemt, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR